Interesting interview. The focus is on non-metastatic castrate resistant prostate cancer. But about
2/3 of the way through the interview Dr. Cookson mentions also that investigations are starting to evaluate apalutamide and enzalutamide (Xtandi) in non-metastatic castrate sensisitive PCa.
I am in the control arm of a trial that has just begun to compare 1) standard treatment -- Degeralix - a.k.a. Firmagon vs. 2) Degeralix plus Apalutamide, vs. 3) Degeralix plus Apalutamide plus abiraterone acetate (Zytiga) in patients like me who have biochemical recurrence and are still castrate sensitive. After the first year patients will have follow-up clinical exams and questionnaires for another 4 years. Beyond that there may be indefinite follow-up by telephone or questionnaire etc.
I'm not disappointed to have been randomized into the standard treatment arm, though I'd have preferred the Degeralix plus Apalutamide arm. For anyone who is potentially eligible and interested, here is a link:/clinicaltrials.gov/ct2/results?cond=Prostate+Cancer&term=aft-19&cntry=&state=&city=&dist=
-2002-PSA 9.4, 5 of 10 cores positive - 30-50%.
-RP 2002. PT3B N0 MX Gleason=7 (3+4), 75% left lobe; small focus rt lobe.
-PSA low of 0.01; slow rise to 0.4.
-SRT 2010. One lymph node targeted. Casodex during SRT
-PSA 0.00 thu 2014;
-0.02 Oct '14; 0.04 Apr '16; 0.51 Jan '17; 2.46 Jan '18, 4.19 Apr '18; 6.62 May '18
-Firmagon May '18 in control group of clinical trial